NCL-1 significantly reduced xenograft tumor growth in the treatment cohorts harboring either a cell line-derived xenograft (Figure 3A), resulting in significantly smaller tumors after 14 d of NCL-1 treatment (Figure 3B). The gene discussed is NUCLEOLIN; the disease is neoplasm.